Murray Goldberg
Directeur/Membre du Conseil chez AYALA PHARMACEUTICALS, INC.
Profil
Murray A.
Goldberg is an Independent Director at Ayala Pharmaceuticals, Inc. and a Venture Advisor at Israel Biotech Fund.
He was previously an Independent Director at Teva Pharmaceutical Industries Ltd., Aerie Pharmaceuticals, Inc., and Old Ayala, Inc. He also served as a Senior Vice President-Administration at Regeneron Pharmaceuticals, Inc. and as the Managing Director-Structured Finance Group at The Chase Manhattan Bank NA.
Additionally, he was the Chief Financial Officer, Treasurer & VP-Finance at PharmaGenics, Inc. Goldberg holds an MBA from The University of Chicago, an undergraduate degree from New York University, and a graduate degree from the London School of Economics & Political Science.
Postes actifs de Murray Goldberg
| Sociétés | Poste | Début |
|---|---|---|
| AYALA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/12/2017 |
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Consultant / Advisor | - |
Anciens postes connus de Murray Goldberg
| Sociétés | Poste | Fin |
|---|---|---|
| ADVAXIS, INC. | Directeur/Membre du Conseil | 19/01/2023 |
| AERIE PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 11/06/2020 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Directeur/Membre du Conseil | 09/06/2020 |
| REGENERON PHARMACEUTICALS, INC. | Directeur Financier/CFO | 03/10/2013 |
PharmaGenics, Inc.
 PharmaGenics, Inc. Miscellaneous Commercial ServicesCommercial Services PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million. | Directeur Financier/CFO | 01/01/1995 |
Formation de Murray Goldberg
| The University of Chicago | Masters Business Admin |
| London School of Economics & Political Science | Graduate Degree |
| New York University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| AYALA PHARMACEUTICALS, INC. | Commercial Services |
| Entreprise privées | 6 |
|---|---|
PharmaGenics, Inc.
PharmaGenics, Inc. Miscellaneous Commercial ServicesCommercial Services PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million. | Commercial Services |
The Chase Manhattan Bank NA
 The Chase Manhattan Bank NA Major BanksFinance The Chase Manhattan Bank NA operates a commercial banking. It provides financial products, services, and advice, planning and treasury management services. The company is located in New York, NY. | Finance |
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
Old Ayala, Inc.
 Old Ayala, Inc. Pharmaceuticals: MajorHealth Technology Old Ayala, Inc. operates as a clinical-stage oncology company. It focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel. | Health Technology |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
